AcelRx Pharma (ACRX) Tops Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
AcelRx Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results
March 2, 2017 4:01 PM ESTREDWOOD CITY, Calif., March 2, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2016.
Corporate and Clinical HighlightsDuring the fourth quarter of 2016, AcelRx submitted a New Drug Application (NDA) under section 505(b)(2) with the U.S. Food and Drug Administration (FDA) for DSUVIA (sufentanil sublingual tablet, 30 mcg) for the treatment of patients experiencing moderate-to-severe... More
